Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?

2011 | journal article; research paper. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?​
Grimmsmann, T. & Himmel, W. ​ (2011) 
European Journal of Clinical Pharmacology67(8) pp. 847​-854​.​ DOI: https://doi.org/10.1007/s00228-011-1014-7 

Documents & Media

228_2011_Article_1014.pdf287.52 kBAdobe PDF

License

Published Version

Special user license Goescholar License

Details

Authors
Grimmsmann, Thomas; Himmel, Wolfgang 
Abstract
Purpose Defined daily doses (DDD) are used for the measurement of drug utilisation. The aim of the study was to analyse whether differences between DDD and prescribed daily doses (PDD) exist for relevant drug classes such as antihypertensive drugs and, if so, whether they primarily depend on drug classes or patient-related factors. Methods Using the data of a large German statutory health insurance scheme, we analysed continuous prescriptions for the following antihypertensive drug classes: thiazide diuretics, beta-blockers, dihydropyridine calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs). We summed the doses of all dispensed drugs per person during a defined time frame. We calculated the PDD (= total dose divided by the number of days) and expressed them as the PDD: DDD ratio (= amount of DDD per day and person). Results During the study period, 149,704 patients continuously received an antihypertensive medication. The average PDD: DDD ratio ranged from 0.84 (beta-blockers) to 1.88 (ARBs) and 2.17 (ACEIs). The average prescribed dosage of each drug class remained unchanged, even if the patients had previously received another antihypertensive drug with another PDD: DDD ratio. For example, if patients were switched from a beta-blocker to an ACEI, the PDD:DDD ratio increased, on average, from 0.79 to 2.17. Vice versa, the ratio decreased for patients with a drug change from an ACEI to a beta-blocker from 2.06 to 0.75. Conclusions Even large differences between DDD and PDD seem to be a matter of drug classes and not primarily of patient characteristics.
Issue Date
2011
Journal
European Journal of Clinical Pharmacology 
Organization
Institut für Allgemeinmedizin 
ISSN
0031-6970

Reference

Citations


Social Media